Characterization of an HIV-Targeted Transcriptional Gene-Silencing RNA in Primary Cells

Anne‐Marie W. Turner, Amanda Ackley, Michael A. Matrone, Kevin V. Morris

Human Gene Therapy · 2011 · 40 citations · 41 references

DOIFull text

Open access

Concepts

Abstract

Small antisense RNAs targeted to the HIV-1 promoter have been shown to remodel the surrounding chromatin to a state unfavorable for transcriptional activation, yet transcriptional gene silencing (TGS) of HIV-1 has, to date, not been shown in primary human cells. We demonstrate here that TGS can reduce viral transcription in primary human CD4+ T cells; however, increasing viral burden results in the loss of this antiviral effect. This observation suggests a critical level at which viral RNA can dilute out effective targeting by TGS-based RNAs. Furthermore, studies into off-target effects have identified a potential interaction between the small nucleolar RNA pathway and the TGS-based antisense RNA, resulting in activation of p53. Although not overtly toxic to primary cells, this represents a novel interaction between antisense RNAs and a cellular pathway that should be considered when pursuing small antisense RNA-based therapeutics. Turner and colleagues demonstrate that transcriptional gene silencing (TGS) can reduce viral transcription in primary human CD4+ T cells, although increasing viral burden resulted in the loss of this antiviral effect. Studies into off-target effects additionally identified a novel potential interaction between the small nucleolar RNA pathway and the TGS-based antisense RNA, resulting in activation of p53.

References

41